Haleon (HLN) Expected to Announce Quarterly Earnings on Thursday

Haleon (NYSE:HLN) is projected to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.2512 per share and revenue of $2.7637 billion for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 3:45 AM ET.

Haleon Price Performance

HLN stock traded up $0.15 during trading on Friday, hitting $11.26. 7,366,103 shares of the company’s stock traded hands, compared to its average volume of 7,263,187. Haleon has a 52 week low of $8.71 and a 52 week high of $11.42. The stock has a market capitalization of $50.12 billion, a price-to-earnings ratio of 28.86 and a beta of 0.19. The business has a fifty day simple moving average of $10.35 and a 200 day simple moving average of $9.77. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.63 and a current ratio of 0.87.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HLN. Jefferies Financial Group reaffirmed a “buy” rating on shares of Haleon in a report on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft lowered Haleon from a “hold” rating to a “sell” rating in a research note on Monday, January 12th. Morgan Stanley restated an “overweight” rating on shares of Haleon in a report on Monday, December 15th. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research report on Thursday, January 22nd. Finally, HSBC upgraded shares of Haleon from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $12.33.

Hedge Funds Weigh In On Haleon

Several hedge funds have recently bought and sold shares of the business. Morgan Stanley grew its holdings in shares of Haleon by 16.0% in the fourth quarter. Morgan Stanley now owns 21,495,383 shares of the company’s stock worth $217,318,000 after purchasing an additional 2,962,856 shares during the last quarter. Bank of America Corp DE boosted its position in Haleon by 116.7% in the 2nd quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after buying an additional 6,669,923 shares during the period. Bank of Montreal Can grew its stake in Haleon by 454.1% in the 4th quarter. Bank of Montreal Can now owns 8,500,496 shares of the company’s stock worth $85,940,000 after acquiring an additional 6,966,416 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in Haleon by 4,315.4% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 8,027,189 shares of the company’s stock worth $81,155,000 after acquiring an additional 7,845,391 shares in the last quarter. Finally, Nuveen LLC increased its position in shares of Haleon by 2.7% during the fourth quarter. Nuveen LLC now owns 6,169,355 shares of the company’s stock worth $62,372,000 after acquiring an additional 159,955 shares during the period. Institutional investors own 6.67% of the company’s stock.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.